F48 LNP

**F48 LNP** is an experimental lipid nanoparticle formulation developed at **Johns Hopkins University** for systemic intracellular delivery of gene-editing proteins to T cells. In the reported mouse studies, F48 LNP encapsulated CRISPR-Cas9 ribonucleoprotein containing a single-guide RNA directed against **PD-1**, producing preferential gene editing in splenic T cells after intravenous administration. PD-1 disruption reduced checkpoint expression in T cells and was evaluated as an immune-checkpoint-blockade strategy in a B16-OVA melanoma model. F48 is a research-stage delivery formulation rather than an approved drug; the precise lipid composition was not disclosed in the available abstract.